Evidence map›Paper›PMID 36943916›Full record

ArticleExpert opinion on pharmacotherapy2023

Acalabrutinib in chronic lymphocytic leukemia.

Enrica Antonia Martino, Antonella Bruzzese, Ernesto Vigna, Enrico Iaccino, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Gianfranco Filippelli, Antonino Neri, Fortunato Morabito and 1 more

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Expert opinion on pharmacotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Inhibitory Potential of theMolecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Enrica Antonia MartinoHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Antonella BruzzeseHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Ernesto VignaHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Enrico IaccinoDepartment of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Francesco MendicinoHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Eugenio LuciaHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Virginia OlivitoHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Gianfranco FilippelliDirezione Generale, Ospedaliera Annunziata, Cosenza, Italy.
Antonino NeriScientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Fortunato MorabitoBiotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
Massimo GentileHematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.ORCID 0000-0002-5256-0726

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellBenzamidesHumansProtein Kinase InhibitorsPyrazinesacalabrutinibBenzamidesProtein Kinase InhibitorsPyrazinesAcalabrutinibchronic lymphocytic leukemiatherapy

Identifiers

PMID36943916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.